<PAGE>
<PAGE>
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
(X) QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended May 31, 1998
OR
( ) TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT
Commission File Number: 0-27380
ECHOCATH, INC.
-----------------------------------------------------------
(Exact Name of Small Business Issuer as specified in its charter)
New Jersey 22-3273101
- ------------------------------------------------ --------------------------
(State or Other Jurisdiction of Incorporation or (I.R.S. Employer
Organization) Identification No.)
P.O. Box 7224, Princeton, NJ 08543
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices)
Issuer's Telephone Number. . .(609) 987-8400
- -------------------------------------------------------------------------------
Former Name, Former Address and Former Fiscal Year, If Changed Since Last
Report
Check whether Issuer (1) has filed all reports required to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
YES X NO
------ ------
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date:
CLASS OF COMMON EQUITY OUTSTANDING AT July 13, 1998
- ------------------------- ----------------------------
Class A common stock (No Par Value) 2,332,430
Class B common stock (No Par Value) 1,191,606
Transitional Small Business Disclosure Format (check one)
YES NO X
------ ------
1
<PAGE>
<PAGE>
ECHOCATH, INC.
INDEX
PART I: FINANCIAL INFORMATION
<TABLE>
<CAPTION>
Page
----
<S> <C>
Item 1: Financial Statements
Balance Sheets,
August 31, 1997 and May 31, 1998 (Unaudited) 3
Statements of Operations for the three months ended
May 31, 1997 (Unaudited), and May 31, 1998 (Unaudited) 4
Statements of Operations for the nine months ended
May 31, 1997 (Unaudited) and May 31, 1998 (Unaudited) 5
Statements of Cash Flows for the nine months ended
May 31, 1997 (Unaudited), and May 31, 1998 (Unaudited) 6
Notes to Financial Statements 7 - 9
Item 2: Management's Discussion and Analysis of
Financial Condition and Results of
Operation 9 - 11
</TABLE>
PART II: OTHER INFORMATION
<TABLE>
<S> <C>
Item 1: Legal Proceedings
Signatures 12
</TABLE>
2
<PAGE>
<PAGE>
ECHOCATH, INC.
BALANCE SHEETS
ASSETS
<TABLE>
<CAPTION>
August 31, 1997 May 31, 1998
--------------- ------------
(Unaudited)
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 788,933 $ 753,764
Accounts receivable -- 69,120
Inventory 200,565 191,666
Prepaid expenses 109,994 48,934
Deferred financing costs -- 15,000
------------ ----------
Total current assets 1,099,492 1,078,484
Furniture, equipment and leasehold
improvements, net 324,243 277,817
Intangible assets, net 264,076 281,435
Other assets 27,827 28,397
------------ --------
$ 1,715,638 $1,666,133
============ ==========
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Note payable $ 540,000 $ 540,000
Accounts payable 90,270 16,872
Accrued expenses 373,145 451,759
Obligations under capital leases,
less current portion 25,852 18,834
------------ ----------
Total current liabilities 1,029,267 1,027,465
Obligations under capital leases 28,702 25,108
Other liabilities 87,519 133,813
------------ ----------
Total liabilities 1,145,488 1,186,386
------------ ----------
Capital contribution subject to repayment 750,000 --
------------ ----------
Stockholders' equity (deficit):
Preferred stock, no par value, 5,000,000 shares
authorized; 280,000 shares of Series B
cumulative convertible issued and outstanding,
senior in liquidation to Class A and Class B
common stock, (liquidation value $1,400,000) 1,393,889 1,393,889
Class A common stock, no par value, 18,500,000
shares authorized; 2,332,430 issued and
outstanding as of May 31, 1998 and 1,886,955
as of August 31, 1997 6,198,611 7,247,834
Class B common stock, no par value, 1,500,000
shares authorized; 1,191,606 shares issued
and outstanding, 308,394 shares retired and
transferred to Class A shares; convertible
into one share of Class A common stock 3,273,470 4,023,470
Accumulated deficit (11,045,820) (12,185,446)
------------- -------------
Total stockholders' (deficit) equity (179,850) 479,747
------------- -------------
$ 1,715,638 $ 1,666,133
============= =============
</TABLE>
See accompanying notes to financial statements.
3
<PAGE>
<PAGE>
ECHOCATH, INC.
STATEMENT OF OPERATIONS
THREE MONTHS ENDED MAY 31, 1997 AND
MAY 31, 1998
(UNAUDITED)
<TABLE>
<CAPTION>
1997 1998
------ ------
<S> <C> <C>
REVENUE:
License fees $ -- $ 254,414
Product sales 142,430 16,080
---------- --------
Total revenue 142,430 270,494
Cost of sales 34,326 10,696
---------- --------
Gross profit 108,104 259,798
Operating expenses:
Research and Development 404,541 242,064
Marketing and General and Administrative 433,169 324,694
----------- ---------
Total operating expense 837,710 566,758
----------- ---------
Loss from operations (729,606) (306,960)
Net interest income (expense) 800 (3,255)
----------- ----------
Net loss $ (728,806) $(310,215)
=========== ==========
Basic and diluted earnings per share (0.32) (0.12)
Weighted average shares of Common Stock 2,277,000 2,690,636
</TABLE>
See accompanying notes to financial statements.
4
<PAGE>
<PAGE>
ECHOCATH, INC.
STATEMENT OF OPERATIONS
NINE MONTHS ENDED MAY 31, 1997 AND
MAY 31, 1998
(UNAUDITED)
<TABLE>
<CAPTION>
1997 1998
---- ----
<S> <C> <C>
REVENUE:
License fees $150,000 1,054,414
Product sales 155,010 16,080
-------- ----------
Total revenue 305,010 1,070,494
Cost of sales 38,629 10,696
-------- ----------
Gross profit 266,381 1,059,798
Operating expenses:
Research and Development 1,142,583 938,563
Marketing and General and Administrative 1,238,599 1,204,125
--------- ----------
Total operating expenses 2,381,182 2,142,688
--------- ----------
Loss from operations (2,114,801) $(1,082,890)
Net interest income (expense) 16,860 (35)
--------- ----------
Net loss $(2,097,941) $(1,082,925)
=========== ===========
Basic and diluted earnings per share (0.92) (0.44)
Weighted average shares of Common Stock 2,277,000 2,602,840
</TABLE>
See accompanying notes to financial statements.
5
<PAGE>
<PAGE>
ECHOCATH, INC.
STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED MAY 31, 1997 AND 1998
(UNAUDITED)
<TABLE>
<CAPTION>
1997 1998
---- ----
<S> <C> <C>
Cash flows from operating activities:
Net loss $(2,097,941) $(1,082,925)
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation and amortization 89,994 88,929
Change in operating assets & liabilities:
(Increase) decrease in trade accounts
receivable 7,500 (69,120)
(Increase) decrease in inventory (52,319) 8,900
Decrease in prepaid expenses 71,565 61,059
Increase in other assets (8,343) (570)
Increase in deferred financing costs -- (15,000)
Decrease in accounts payable (1,435) (9,090)
Increase (decrease) in accrued expenses
and due from related parties (90,586) 14,304
Increase in other liabilities 8,494 46,294
---------- ---------
Net cash used in operating activities (2,073,071) (957,219)
---------- ---------
Cash flows from investing activities:
Purchase of furniture, equipment and (144,074) (28,646)
leasehold improvements
Purchase of intangible assets (37,442) (31,215)
-------- --------
Net cash used in investing
activities (181,516) (59,861)
--------- --------
Cash flows from financing activities:
Principal payments on capital lease
obligations (18,713) (10,612)
Repayment from shareholder 101,899 --
Net proceeds from initial public offering and
over-allotment option (14,273) 223
Proceeds from issuance of preferred stock 1,374,989 --
Issuance of Class A common stock -- 1,049,000
Class B preferred dividends (18,900) (56,700)
--------- --------
Net cash provided by financing activities 1,425,002 981,911
--------- --------
Net decrease in cash and cash
equivalents (829,585) (35,169)
Cash and cash equivalents, beginning of period 2,387,691 788,933
----------- ---------
Cash and cash equivalents, end of period $1,558,106 $753,764
----------- ---------
Supplemental disclosure of cash flow information:
Interest expense $ 46,646 $ 44,424
---------- ---------
Supplemental disclosure of noncash information:
Equipment acquired under capital lease $ -- $ 8,190
---------- ---------
</TABLE>
See accompanying notes to financial statements.
6
<PAGE>
<PAGE>
ECHOCATH, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
NOTE A: GENERAL AND BUSINESS
The summary financial statements included herein have been prepared, without
audit, pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to such rules and
regulations, although EchoCath, Inc. (the "Company") management believes that
the disclosures are adequate to make the information presented not misleading.
It is suggested that these summary financial statements be read in conjunction
with the financial statements and the notes thereto included in the Company's
Form 10-KSB for the fiscal year ended August 31, 1997.
In the opinion of management, all adjustments (consisting solely of normal
recurring adjustments) necessary to present fairly the financial position,
results of operation and cash flows at May 31, 1997 and 1998 have been made.
NOTE B:
Inventories are summarized as follows:
<TABLE>
<CAPTION>
May 31, 1998
------------
<S> <C>
Raw Materials $ 59,126
Work In Process 5,401
Finished Goods 127,139
--------
$191,666
========
</TABLE>
NOTE C:
On July 7, 1995, the Company entered into an agreement with Alliance Partners
("Alliance") which amended a previously existing agreement. In accordance with
the new agreement, the partners of Alliance and certain other entities and
individuals became entitled to receive a 35% equity interest in the Company in
exchange for Alliance's repayment of the Company's $750,000 of outstanding
borrowings under the Company's bank demand note payable, which was paid in full
in August 1995. The payment of such indebtedness was treated as a capital
contribution; however, if 75% of the Class B warrants to be issued in connection
with the initial public offering are subsequently exercised providing the
Company with $23,040,000 in proceeds, then $750,000 of such proceeds will be
repaid to Alliance. In addition, the new agreement provided that funds
previously advanced to the Company by the partners of Alliance (aggregating
$1,050,368 as of January 1996) is treated as permanent capital. On September 7,
1995, the partners of Alliance and certain other entities and individuals
received 525,000 shares of Class B common stock pursuant to this agreement. As
of October 31, 1997, Alliance released the $750,000 contingent payment in
exchange for 50,000 shares of Class A common stock and an option to purchase
50,000 shares of Class A common stock, thereby converting the Company's
contingent liability to equity. The option is exercisable at $2.00 per share of
Class A common stock and expires six years from the date of grant. This
transaction was treated as a capital contribution, consistent with the original
Alliance transaction.
NOTE D:
LICENSE AGREEMENTS WITH MEDTRONIC, INC.
On December 30, 1996, the Company entered into an exclusive license agreement
with Medtronic, Inc. for the licensing of EchoMark'r' and ColorMark'r'
proprietary technologies for certain medical procedures. Under the agreement the
Company expects to receive a series of payments totaling up to $950,000 after
the completion of certain milestones. As of July 1, 1998 total payments under
this agreement were $200,000.
The Company entered into an exclusive license agreement dated February 27, 1997
with EP MedSystems, Inc. (EP MedSystems). The agreement provides that certain
products of the Company can be incorporated into the EP MedSystems' diagnostic
catheter line. The Company expects to receive development milestone payments of
up to
7
<PAGE>
<PAGE>
$700,000. The milestones include the testing of a limited series of
patients, system capability demonstration, and the sale of a limited quantity of
product. When products are commercially available the Company will receive
royalties under the terms of the agreement. The Company has received no
milestone payment nor has it earned any royalties to date under this agreement.
The agreement provides that any royalty payment can be reduced, but not to an
amount below zero, by an amount equal to the amount of any dividends under the
Company's Series B cumulative preferred stock which are accrued but not paid as
of that date. As of May 31, 1998, the Company has $94,500 of accrued preferred
stock dividends.
On October 30, 1997, the Company announced it had reached a second definitive
licensing and development agreement with Medtronic, Inc. Pursuant to the terms
of this Agreement, the Company, among other things: (i) granted Medtronic an
exclusive license to make, have made, use, sell and have sold products utilizing
the Company's ColorMark and EchoMark technologies in guiding devices during
cardiothoracic surgical procedures: and (ii) granted Medtronic the exclusive
right and option at any time until July 31, 1998 to acquire a worldwide
exclusive license to the Company's EchoEye and EchoFlow technologies for use in
guiding device during cardiothoracic surgical procedures.
In consideration of the grant of the exclusive rights to Medtronic, Medtronic
agreed to pay to the Company a combined total of $1,800,000 million, which
amount includes, among other things: (i) $800,000 paid to the Company in upfront
licensing fees: (ii) $1,000,000 for the purchase of 363,636 restricted shares of
the Company's Class A common stock issued to Medtronic Asset Management, Inc.
wholly-owned subsidiary of Medtronic; and (iii) future payments by Medtronic to
the Company which include minimum annual royalties upon product
commercialization.
NOTE E:
PREFERRED STOCK SUBSCRIPTION AGREEMENT
The Company entered into a subscription agreement dated February 27, 1997 with
EP MedSystems. EP MedSystems purchased 280,000 shares of the Company's Series B
Cumulative Convertible Preferred Stock for $1,400,000. The agreement provides
for an annual dividend of $.27 per share. The Company can redeem the Preferred
Stock if certain performance goals of the Class A Common Stock are achieved. The
Series B Preferred Stock is convertible into Class A Common Stock. The Series B
Cumulative Convertible Preferred Stock to Class A Common Stock will be at the
conversion rate of one share of Class A Common Stock for each 1.2 shares of
Series B Cumulative Preferred Stock through 1999. Thereafter, the conversion
rate shall be one share of Class A Common Stock issuable for each 1.3 shares of
Series B Convertible Preferred Stock (see Part 2: Other Information - Item 1,
Legal Proceedings).
NOTE F:
LOSS PER SHARE
As of February 28, 1998, the Company adopted Statement of Financial Accounting
Standards No. 128, Earnings Per Share. Basic loss per share is based on net loss
for the relevant period, divided by the weighted average number of common shares
outstanding during the period.
Diluted loss per share is based on net loss for the relevant period, divided by
the weighted average number of common shares outstanding during the period.
Common share equivalents, such as outstanding stock options and preferred stock
are not included in the calculation since the effect would be antidilutive.
NOTE G:
On February 26, 1998, the Company was notified by The NASDAQ Stock Market,
Inc. that based on the quarter ended November 30, 1997 Form 10-QSB filing, the
Company did not satisfy NASDAQ's minimum equity requirements of $2 million and
that if the Company did not correct this matter it would be delisted from the
NASDAQ Smallcap Market. On June 1, 1998 the Company filed for an exception to
the minimum equity requirement, which NASDAQ has extended. On June 8, 1998, the
Company requested a hearing to review the initial finding by the NASDAQ listing
qualification staff. A hearing date of July 31, 1998 has been set to review the
continuing listing of the Company. Currently, the Company is exploring various
opportunities which could potentially increase equity over the NASDAQ minimum
equity requirements. However, there can be no
8
<PAGE>
<PAGE>
assurances that any of these opportunities will occur or that the Company will
not be delisted from the NASDAQ Smallcap Market.
ITEM II: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION
GENERAL
Certain statements in this Report on Form 10-QSB ("Report") under the caption
"Management's Discussion and Analysis of Financial Condition and Results of
Operation" and elsewhere constitute "forward-looking statements" within the
meaning of Private Securities Litigation Reform Act of 1995, including, without
limitation, statements regarding future cash requirements. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance, or achievements of the Company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Such factors include, among others, the following: limited
commercial operations; no assurances of success; need for additional financing;
uncertainty of market acceptance; reliance on collaborative agreements;
competition and rapid technological change; failure to receive or delays in
receiving regulatory approval; limited manufacturing and assembly experience;
limited marketing and sales experience; dependence upon, and need for, key
personnel; uncertain protection of patent and proprietary rights; lack of
reimbursement; general economic and business conditions; industry capacity;
industry trends; demographic changes; changes in business strategy or
development plans; quality of management; availability, terms and deployment of
capital; potential adverse impact of the U.S. Food and Drug Administration (FDA)
and other government regulations; limitations on third party reimbursement;
potential product liability; risk of loss in lawsuit; risk of low price stocks;
and other factors referenced in this Report. When used in this Report,
statements that are not statements of material fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words
"anticipates," "plans," "intends," "expects" and similar expressions are
intended to identify such forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
RESULTS OF OPERATIONS
Nine Months Ended May 31, 1998 and 1997
REVENUE:
The Company had revenues of $1,070,474 and $305,010 for the nine months ended
May 31, 1998 and 1997, respectively. License fees represented 98.5% of revenue
and product sales represents 1.5% for the nine months ended May 31, 1998.
Product sales represented 50.8% of revenue, and license fees represented 49.2%
of revenue for the nine months ended May 31, 1997.
The Company had cost of sales of $10,696 associated with revenues for the nine
months ended May 31, 1998 and $38,629 for the nine months ended May 31, 1997.
RESEARCH AND DEVELOPMENT:
Research and Development expenses decreased $204,020 or 17.9% during the nine
months ended May 31, 1998 because of the reimbursement of certain development
expenses under the terms of a license and development agreement, greater
allocation to administration salary and related expenses by management, and a
lower level of FDA consulting fees.
9
<PAGE>
<PAGE>
SELLING, GENERAL AND ADMINISTRATIVE:
Selling, general and administrative expenses decreased $34,474 or 2.8% during
the nine months ended May 31, 1998. The Company eliminated a marketing employee
and a marketing consultant and certain related expenses associated with the
reduction. This was partially offset by a large increase in legal expenses
resulting from the EP MedSystems litigation, satisfying listing requirements on
the NASDAQ Smallcap Market, the license agreement with Medtronic and an
agreement with Alliance Partners to reclassify a contingent liability to
permanent capital. The Company also recognized $49,000 of compensation
associated with the issuance of Class A common stock to Alliance Partners.
RESULTS OF OPERATIONS
Three Months Ended May 31, 1998 and 1997
REVENUE:
The Company had revenue of $270,494 and $142,430 for the three months ended May
31, 1998 and 1997 respectively. License fees represented 94.1% of revenue and
product sales represented 5.9% for the three months ended May 31, 1998. Product
sales represented 100% of the revenue for the three months ended May 31, 1997.
The Company had cost of sales of $10,696 associated with revenues for the three
months ended May 31, 1998 and $34,326 for the three months ended May 31, 1997.
RESEARCH AND DEVELOPMENT:
Research and Development expenses decreased $162,477 or 40.2% during the three
months ended May 31,1998 because of the reimbursement of certain development
expenses under the terms of a license and development agreement, greater
allocation to administrative salary and related expenses by management, and a
lower level of FDA consultant fees compared to the quarter ended May 31, 1997.
SELLING, GENERAL AND ADMINISTRATIVE:
Selling, general and administrative expenses decreased $108,475 or 25.0% during
the three months ended May 31, 1998 because of a decrease in legal expenses for
the quarter, (year to date legal expenses are up substantially). Reduction in
salary and related expenses in both Sales and Marketing and Administration and
the reduction in consulting expenses compared to the quarter ended May 31, 1997.
LIQUIDITY AND CAPITAL RESOURCES
The Company projects that it has sufficient funds until to the end of its fiscal
year. In order to continue operations thereafter, the Company will be required
to raise additional funds. The Company is in the process of arranging a proposed
financing with a placement agent. However, there can be no assurances that such
financing will be consummated. The Company also believes that additional cash
resources should be available through financing provided through the completion
of license agreements and strategic alliances. There can be no assurance that
the Company will be able to complete the aforementioned license agreements,
strategic alliances or financing on acceptable terms or at all. The Company has
no binding commitments from any third parties to provide funds to the Company.
There can be no assurances that the Company will be able to obtain financing
from any other sources on acceptable terms or at all.
PART II: OTHER INFORMATION
Item 1: Legal Proceedings
On October 16, 1997, EP MedSystems delivered to the Company a complaint (the
"Complaint") filed in the United States District Court for the District of New
Jersey in connection with the Company's sale of securities to EP MedSystems
pursuant to a Subscription Agreement, dated as of February 27, 1997, by and
between the Company and EP MedSystems. In the Complaint, EP MedSystems alleges
that the Company violated 'SS' 10(b) of the Exchange Act and committed common
law fraud in connection with EP MedSystems' purchase of securities
10
<PAGE>
<PAGE>
from the Company. EP MedSystems requested unspecified compensatory damages,
costs, attorneys' fees and punitive damages. On November 26, 1997, pursuant to
an order of the Court, the Company filed an Answer, without prejudice to its
right to move to dismiss the Complaint, denying the material allegations of the
Complaint, and asserting a counterclaim against EP MedSystems seeking its costs
and expenses in the action, including its attorneys' fees, based on EP
MedSystems' breach of the Subscription Agreement. On December 3, 1997, EP
MedSystems filed an Amended Complaint, also alleging violations of 'SS' 10(b)
of the Exchange Act, and common law fraud. Pursuant to Court order, the
Company's Answer was due December 10, 1997, also without prejudice to the
Company's right to move to dismiss. On December 10, 1997, the Company filed an
Answer to the Amended Complaint; again denying the material allegations of the
complaint, and asserting a counterclaim against EP MedSystems based on EP
MedSystems' breach of the Subscription Agreement. On December 17, 1997, the
Company served on EP MedSystems a motion to dismiss the Complaint. This motion
has been fully briefed and has been submitted to the Court.
The Company believes, after discussion with counsel, that the Complaint is
without merit and intends to defend itself vigorously.
Item 2: Changes in Securities and use of Proceeds - None
Item 3: Defaults Upon Senior Securities - None
Item 4: Submission of Matters to a Vote of Security Holders -None
Item 5: Other Information - None
Item 6: Exhibits and Reports on Form 8-K
A) Exhibits
27) Financial Data Schedule
B) There were no reports on Form 8-K filed during the quarter
ended May 31, 1998.
11
<PAGE>
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this Report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: July 14, 1998
EchoCath, Inc.
------------------
(Registrant)
By: /s/ Frank DeBernardis
------------------------------
Frank DeBernardis
President, Chief Executive
Officer,
Principal Financial and
Accounting Officer
STATEMENT OF DIFFERENCES
The registered trademark symbol shall be expressed as................. 'r'
The section symbol shall be expressed as.............................. 'SS'
12
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<FISCAL-YEAR-END> AUG-31-1998
<PERIOD-START> SEP-01-1997
<PERIOD-END> MAY-31-1998
<PERIOD-TYPE> 3-MOS
<CASH> 753,764
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 191,666
<CURRENT-ASSETS> 1,078,484
<PP&E> 689,106
<DEPRECIATION> 411,289
<TOTAL-ASSETS> 1,666,133
<CURRENT-LIABILITIES> 1,027,465
<BONDS> 0
<COMMON> 11,271,304
0
1,393,889
<OTHER-SE> 479,747
<TOTAL-LIABILITY-AND-EQUITY> 1,666,133
<SALES> 0
<TOTAL-REVENUES> 1,070,494
<CGS> 0
<TOTAL-COSTS> 2,153,384
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 44,424
<INCOME-PRETAX> (1,082,925)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,082,925)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,082,925)
<EPS-PRIMARY> 0
<EPS-DILUTED> 0
</TABLE>
